Hikma Pharmaceuticals (LON:HIK) Stock Price Down 14.1% Following Analyst Downgrade

Hikma Pharmaceuticals PLC (LON:HIK)’s share price was down 14.1% on Thursday after Berenberg Bank lowered their price target on the stock from GBX 2,510 to GBX 2,300. Berenberg Bank currently has a buy rating on the stock. Hikma Pharmaceuticals traded as low as GBX 1,522 and last traded at GBX 1,522. Approximately 166,325,172 shares traded hands during trading, an increase of 7,989% from the average daily volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

HIK has been the topic of a number of other research reports. JPMorgan Chase & Co. lowered their price objective on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating on the stock in a research report on Friday. Peel Hunt restated a “buy” rating and issued a GBX 2,170 target price on shares of Hikma Pharmaceuticals in a research note on Friday. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,360 price target on shares of Hikma Pharmaceuticals in a report on Friday. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a report on Tuesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of GBX 2,416.

Insider Activity

In other Hikma Pharmaceuticals news, insider Mazen Darwazah purchased 315,000 shares of the firm’s stock in a transaction on Thursday, November 6th. The shares were purchased at an average cost of GBX 1,601 per share, with a total value of £5,043,150. Also, insider Laura Balan Balan bought 3,500 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was acquired at an average price of GBX 1,821 per share, for a total transaction of £63,735. Insiders have bought a total of 332,500 shares of company stock worth $533,130,500 over the last quarter. Corporate insiders own 17.77% of the company’s stock.

Hikma Pharmaceuticals Stock Performance

The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. The company has a fifty day moving average price of GBX 1,730.88 and a 200 day moving average price of GBX 1,894.04. The stock has a market cap of £3.50 billion, a PE ratio of 9.47, a P/E/G ratio of 2.38 and a beta of 0.41.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.